Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2

Conditions

Neuroendocrine Tumors 117Neoplasms 42Carcinoma, Neuroendocrine 34Carcinoma, Non-Small-Cell Lung 32Carcinoid Tumor 30Multiple Endocrine Neoplasia Type 1 28Melanoma 27Breast Neoplasms 27Colorectal Neoplasms 25Small Cell Lung Carcinoma 24Pancreatic Neoplasms 22Carcinoma, Renal Cell 22Gastro-enteropancreatic neuroendocrine tumor 21Neoplasm Metastasis 20Lung Neoplasms 19Sarcoma 18Carcinoma, Hepatocellular 18Adrenocortical Carcinoma 18Stomach Neoplasms 17Uterine Cervical Neoplasms 15Thyroid Neoplasms 15Thyroid Carcinoma, Anaplastic 15Thyroid Cancer, Papillary 15Pheochromocytoma 15Ovarian Neoplasms 15Carcinoma 14Prostatic Neoplasms 13Paraganglioma 13Head and Neck Neoplasms 13Colonic Neoplasms 13

Interventions

Sunitinib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neuroendocrine Tumors × Endocrine × Clear all
NCT02842749 2025-02-10

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Novartis

Phase 4 Completed
61 enrolled 9 charts
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

NCT02282059 2024-06-20

The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors

Pfizer

Completed
100 enrolled 13 charts
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡